SELECT Trial: Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes

What was the SELECT trial?

SELECT — Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity — was a randomized, double-blind, placebo-controlled cardiovascular outcomes trial sponsored by Novo Nordisk and published in the New England Journal of Medicine in 2023 (PMID 37952131).

It asked a question that earlier weight-loss studies could not: does a weight-management drug actually reduce hard cardiovascular events — heart attacks, strokes and cardiovascular deaths — rather than just moving the number on the scale? To answer that, SELECT was designed as an event-driven trial, running until enough cardiovascular events had accumulated to give a definitive read. Participants were followed for a mean of 39.8 months. The trial is registered as NCT03574597 on ClinicalTrials.gov.

This is a different kind of study from the weight-loss trials that made semaglutide famous. Where STEP 1 measured how much weight semaglutide produced, SELECT measured whether the drug changed cardiovascular outcomes in people who already had heart disease.

Who was in it?

SELECT enrolled 17,604 adults, split into 8,803 assigned to semaglutide and 8,801 to placebo. To be eligible, participants had to be 45 years of age or older, have a body-mass index of 27 or greater, and have preexisting cardiovascular disease — but they could not have a history of diabetes.

That last criterion is the point of the whole trial. GLP-1 receptor agonists began as diabetes drugs, so any cardiovascular benefit could plausibly be attributed to better blood-sugar control. By excluding people with diabetes, SELECT tested whether semaglutide protects the heart in a population defined by weight and established cardiovascular disease, independent of its glucose-lowering role. It is a large, secondary-prevention population: everyone enrolled already had cardiovascular disease and was therefore at elevated risk of a further event.

What did participants receive?

Participants were randomly assigned to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or a matching placebo, added on top of standard-of-care cardiovascular treatment. The 2.4 mg weekly dose is the same maintenance dose approved for chronic weight management as Wegovy; the underlying molecule is covered in our semaglutide research summary.

Describing the assigned regimen is reporting what the trial did — it is not a dosing instruction. Semaglutide is prescription-only, and the dose any individual might use is a clinical decision, not something to infer from a trial protocol.

Primary results

The primary endpoint was a composite of three hard outcomes: death from cardiovascular causes, non-fatal myocardial infarction (heart attack), or non-fatal stroke — often abbreviated as MACE, for major adverse cardiovascular events.

Over the mean 39.8-month follow-up, a first primary-endpoint event occurred in 569 of the 8,803 participants on semaglutide (6.5%) and in 701 of the 8,801 on placebo (8.0%). That corresponds to a hazard ratio of 0.80, with a 95% confidence interval of 0.72 to 0.90 and P<0.001 — a roughly 20% relative reduction in the risk of a major cardiovascular event.

Both the relative figure (a hazard ratio of 0.80) and the absolute figures (6.5% versus 8.0%) describe the same finding. The relative reduction sounds larger; the absolute difference — about 1.5 percentage points over more than three years — is what a clinician weighs against cost and side effects for a given patient.

Secondary results

Beyond the primary composite, SELECT was structured to examine confirmatory secondary cardiovascular endpoints and, consistent with semaglutide's known effects, participants lost weight and saw movement in several cardiometabolic measures. Because this page reports only figures confirmed in the peer-reviewed record, we do not attach specific numbers to individual secondary endpoints here; the direction of the overall result is captured by the primary endpoint above. For the weight-loss magnitude semaglutide produces in a dedicated obesity trial, see our summary of STEP 1, and the broader class comparison in peptides for weight loss.

One nuance worth stating plainly: SELECT reported that the cardiovascular benefit emerged in a population selected for weight and heart disease, but the trial was not built to disentangle how much of that benefit came from weight loss versus other effects of the drug. It is a clinical-outcome result, not a mechanistic one.

Safety and side effects reported

The tolerability picture was consistent with the known profile of GLP-1 receptor agonists. The most visible safety signal in the trial was discontinuation: 16.6% of participants in the semaglutide group stopped the study drug because of adverse events, compared with 8.2% in the placebo group (P<0.001). Gastrointestinal effects are the typical driver of that gap in this drug class, though this page reports only the discontinuation figures stated in the published record rather than assigning rates to specific symptoms.

For a fuller picture of the side effects seen across the GLP-1 class — nausea, diarrhea, vomiting and constipation, worst during dose escalation, plus the boxed thyroid warning and contraindications — see the dedicated sections in our weight-loss peptides guide.

Limitations and what it does not prove

SELECT is a landmark trial, but it has boundaries that matter when the headline gets quoted:

• It studied a specific population. Everyone enrolled was 45 or older, had a BMI of 27 or more, had established cardiovascular disease, and did not have diabetes. The result applies most directly to people like those enrolled — it does not automatically extend to primary prevention in otherwise healthy people, or to people with diabetes.
• It does not isolate a mechanism. The trial reports a clinical outcome. It cannot prove how much of the benefit came from weight loss, blood-pressure or lipid changes, direct vascular effects, or a combination.
• It is a comparison against placebo, not against other drugs. SELECT shows semaglutide beat placebo on cardiovascular events; it does not rank it against other GLP-1 or GIP/GLP-1 agents for that outcome.
• It reflects continued treatment. Participants were on the drug throughout follow-up. It does not describe what happens to cardiovascular risk if treatment stops.

None of this diminishes the finding. It simply keeps it the right size: strong evidence in a defined, high-risk group, not a universal claim.

Why the SELECT trial matters

SELECT was the first time a drug approved for weight management was shown to reduce major adverse cardiovascular events. That is a genuine milestone. For decades, obesity pharmacology was haunted by drugs that produced weight loss but were later withdrawn for cardiovascular or psychiatric harm, which is exactly why regulators came to demand cardiovascular outcome data. SELECT delivered that data on the positive side of the ledger.

The practical consequence is that semaglutide's story shifted from "how much weight does it take off" to "what clinical outcomes does it change." It reframed the newer GLP-1 based drugs as metabolic and cardiovascular medicines rather than cosmetic ones, and it influenced how the FDA, the EMA and health-technology bodies position the class. For the wider map of which weight-loss peptides have this caliber of evidence — and which have none — see our pillar guide on peptides for weight loss and the mechanism explainer on GLP-1 receptor agonists.

Frequently asked questions

Sources

This summary traces to the peer-reviewed publication and trial registration:

1. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — New England Journal of Medicine, 2023; PubMed 37952131.
2. SELECT (semaglutide cardiovascular outcomes) — ClinicalTrials.gov NCT03574597.
3. Drug reference record: semaglutide.

Related research